We previously demonstrated that Siglec-15, a member of the
Siglec family of
glycan-recognition
proteins, is expressed on a subset of macrophages and preferentially recognizes the sialyl-Tn (sTn)
antigen, a
tumor-associated
glycan structure. In this study, we report on the
biological significance of the Siglec-15-mediated interaction between monocytes/macrophages and
cancer cells. Siglec-15 is expressed on tumor-associated macrophages (TAMs) in various human
tumor tissues. We further demonstrated that its expression is substantially elevated in
macrophage colony-stimulating factor-induced M2-like macrophages, which produced more
transforming growth factor-β (TGF-β) in response to sTn-positive cells than to negative cells. We designed a co-culture model of THP-1 (human monocytic
leukemia) cells and H157 (human lung
carcinoma) cells mimicking the interaction between monocytes/macrophages and
cancer cells that recapitulated the enhanced TGF-β production in Siglec-15 expressing THP-1 cells by the cellular interaction with sTn expressing H157 cells. The enhanced TGF-β production required a direct interaction between the two cell lines through
sialic acids. Siglec-15 associates with adaptor
protein DNAX activation
protein of 12 kDa (DAP12) at the binding determinant Lys(274) in the transmembrane domain and transduces a signal to
spleen tyrosine kinase (Syk). The enhanced TGF-β secretion was significantly attenuated by Syk inhibitor treatment of THP-1 cells or by substitution of the Siglec-15 Lys(274) to Ala, which disrupts the molecular interaction between Siglec15 and DAP12. These findings indicate that Siglec-15 recognizes the tumoral sTn
antigen and transduces a signal for enhanced TGF-β secretion in TAMs and further suggest that Siglec-15 on macrophages may contribute to
tumor progression by the TGF-β-mediated modulation of intratumoral microenvironments.